Please upgrade your browser.
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-lab
In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon alfa-2a.
Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer
Although Renal Cell Cancer (RCC) is known to be immunogenic, clinical efficacy of various immunotherapeutic approaches remains unsatisfactory. Novel targeted therapies showing cytostatic rather than cytotoxic activity are unable to cure RCC patients. In our studies, we evaluated the therapeutic efficacy of whole-cell vaccine based on irradiated murine RENCA cells genetically modified to secrete designer cytokineHyper-IL6 (H6)comprising IL-6 and soluble IL-6 receptor. An orthotopic RCC model based on a subcapsular implantation of RENCA cells into kidneys of Balb/C mice was employed.
Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma
OBP-301 (a telomerase-specific, replication-competent adenovirus with hTERT promoter) was constructed in a previous study and it showed a strong anticancer effect by inducing cell lysis in human lung and prostate cancer cells. This study investigated the effectiveness of a combination therapy of OBP-301 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was confirmed in vitro in the RENCA cancer cells.
Renal cell carcinoma is the most lethal of all urologic malignancies with a high metastatic potential. Approximately 25% of patients present with stage IV disease and up to 40% of patients have disease recurrence after nephrectomy. Computed Tomography is an important imaging modality for initial diagnosis and restaging of this patient population. Although extremely rare, metastatic clear cell renal carcinoma has been reported to metastasize to the gallbladder.
Maximum tolerated dose chemotherapy followed by metronomic chemotherapy a method using frequent low doses plus a multikinase inhibitor improved PFS and response rates in patients with metastatic renal cell carcinoma, according to the findings of a phase-2 trial.
The Use of the American Society of Anesthesiology Classification as a Prognostic Factor in Patients with Renal Cell Carcinoma
The authors analyzed whether the American Society of Anesthesiology classification could be used as a prognostic factor in renal cell carcinoma. The ASA classification could be used as a prognostic factor in renal cell carcinoma.
NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation
NEDD8 ultimate buster 1 (NUB1) is an interferon (IFN)-inducible protein that downregulates NEDD8 expression and its conjugation system. Although overexpression of NUB1 induces a growth-inhibitory effect in cells, the mechanisms underlying the anti-mitogenic actions of NUB1 in cancer cells remain uncertain. We investigated the anti-cancer effects of NUB1 in human renal cell carcinoma (RCC) cells.
I had kidney cancer in 2007, in the U.S., I got a CAT scan in 24 hours and had the surgery that saved my life within two weeks. Under the Canadian system, I would have waited at least six months for the CAT scan perhaps over a year, the cancer would have killed me long before then.
George Milton Lopeman Jr., 64, Gardner, died peacefully surrounded by family on Sunday, January 17, 2010, at Villa St. Francis Nursing Home, Olathe, after a long battle with cancer.
|Powered by NeonCRM|